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significant effect on opioid overdose hospital admission. Given the lack of infor-
mation in this field of research, especiallywhen considering clinical outcomes, this
is an important addition to the literature.
PMH66
MULTIMORBIDITY AND DEPRESSION TREATMENT
Vyas A, Sambamoorthi U
West Virginia University, Morgantown, WV, USA
OBJECTIVES: We estimate the rates and types of depression treatment among
individuals with multimorbidity and depression and compare these to individuals
without multimorbidity. We also examine the relationship between multimorbid-
ity and depression treatment after controlling for demographic, socio-economic,
access to care, life-style factors and the number of visits to either office-based
provider or outpatient hospital clinics.METHODS:We did cross-sectional analysis
of 1,376 individuals of age above 21, with depression and at least one chronic
physical condition in the following clusters: cardio-metabolic (diabetes or heart
disease or hypertension), respiratory (chronic obstructive pulmonary disease or
asthma) and musculoskeletal (osteoarthritis or rheumatoid arthritis or osteoporo-
sis) from the 2007 Medical Expenditure Panel Survey (MEPS). Chi-square tests, lo-
gistic regression and multinomial logistic regressions were performed to analyze
the rates and types of depression treatment among various chronic clusters. All
analysis accounted for the MEPS survey design. RESULTS: Of our study sample,
56.2% reported use of antidepressants, 21.4% had psychotherapy with or without
antidepressants and 22.4% reported no depression treatment at all. The individuals
in “respiratory only” and “musculoskeletal only” were less likely to be on antide-
pressants and those in “respiratory only” group were less likely to opt for psycho-
therapy with or without antidepressants in the unadjusted model. After adjusting
for all demographic, socio-economic, access to care, life-style factors and number
of visits, only those in “respiratory only” group were less likely to be treated with
psychotherapy with or without antidepressants. CONCLUSIONS: Presence of mul-
timorbidity is not a barrier to depression treatment suggesting that competing
demands due to multimorbidity may not affect depression treatment. Also the
individuals in ‘respiratory only’ group were less likely to be on psychotherapy.
Therefore, further studies are needed to explore the relationship between psycho-
therapy for depression treatment and respiratory conditions.
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OBJECTIVES: The objective of this study was to identify the national rates of co-
prescribing cholinesterase inhibitors with anticholinergic urinary incontinence
medications using the National Ambulatory Medical Care Survey (NAMCS) and the
National Hospital Ambulatory Medical Care Survey (NHAMCS). Anticholinergic
classes of medications have a mechanism of action that opposes the cholinest-
erase inhibitors; therefore, when taken concomitantly the effectiveness of these
medications potentially decreases. The objective of this study was to describe the
concomitant prescribing of cholinesterase inhibitors and anticholinergic drugs in-
dicated for urinary incontinence. METHODS: This study was a retrospective, ob-
servational, cross-sectional, database analysis using data from the 2006-2008
NAMCS and NHAMCS outpatient departments. Patient visits that included a pre-
scription for a cholinesterase inhibitor alone or combined with an anticholinergic
medication approved for urinary incontinence were analyzed. The data was
weighted to produce national estimates and analyzed using descriptive statistics.
RESULTS: Over the 3 year period there were 13,345,926 visits including cholinest-
erase inhibitors. Of the visits including a cholinesterase inhibitor, 5.5% (n737,064)
also included a prescription of an anticholinergic urinary incontinencemedication.
The most commonly prescribed cholinesterase inhibitor was donepezil
(n11,173,472; 83.5%). The majority of patient visits that included the prescription
of both a cholinesterase inhibitor and an anticholinergic medication weremade by
patients over 80 years of age (n404,359; 54.9%). The most common physician
specialty to prescribe both cholinesterase inhibitors alone (n6,587,573; 49.2%) and
the combination with an anticholinergic medication (n333,135; 45.2%) were fam-
ily practitioners and general practice/internal medicine. Urologists and obstetri-
cians/gynecologists represented the prescribing physicians in 16.8% (n123,465) of
visits with combination therapy, whereas they accounted for 3.1% (n415,818) of
the cholinesterase inhibitor prescribing. CONCLUSIONS: Cholinesterase inhibitors
and anticholinergic urinary incontinence medications were inappropriately pre-
scribed together. Educating health care providers and patients about this potential
interaction can optimize drug therapy for patients on cholinesterase inhibitors.
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OBJECTIVES: Pharmacologic treatment has a major role in the management of
depression, but concerns about the safety of antidepressants, and in particular the
increased risk of suicide, have prompted FDA blackbox warnings. The objective of
this analysis was to describe the trends in utilization of prescription antidepres-
sants over the past decade and interpret these in the context of FDA actions over
that same time period.METHODS: National prescription data were obtained from
IMS XponentTM database for the period January 1999-December 2009 (inclusive).
Total prescription counts were determined for TCAs, SSRIs, and SNRIs. The FDA
website was reviewed to identify the dates of new warnings or safety-related la-
beling changes, including major warnings in 2004 and 2007. RESULTS: Total pre-
scriptions for antidepressants grew from10.9million in 1999 to 19.3million in 2009,
with only a temporary decline occurring in 2004-2005 which corresponds with the
initial FDAwarning.While the warnings applied to all antidepressants, differences
in utilization patterns between classes are apparent. TCAs declined in use, while
both SNRI and SSRI prescriptions increased over the decade, although SNRI utili-
zation leveled-off after the 2007 expansion of the FDA blackbox warning that ap-
plied to young adults (18-24). CONCLUSIONS: Despite continuing expansion of the
scope of the FDA blackbox warnings, overall antidepressant utilization increased
over the decade, although the rate of increase appears to have slowed in the past
two years.
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OBJECTIVES:WAVE-bd (WideAmbispectiVE study of the clinicalmanagement and
burden of bipolar disorder [BD]) is ongoing to address limitations of longitudinal BD
studies to date. As part of this study, healthcare utilization among patientswith BD
was assessed in amultinational BD patient cohort.METHODS:Multinational, mul-
ticenter, non-interventional, longitudinal study of patients diagnosedwith BDwith
1 mood event in the preceding 12 months (retrospective data collection from
indexmood event to enrollment, followed by aminimum of 9months’ prospective
follow-up). Site and patient selection provided a representative sample of patients
cared for in each country, including medical health centers, clinics, private set-
tings, hospitals or specialized units.RESULTS: In total, 2880 patients (mean age 46.5
years [SD: 13.3]; 62% female) were recruited from 10 countries. During the retro-
spective period, 94.3% of patients received usual treatment for BD, which included
atypical antipsychotics, anticonvulsants, antidepressants, lithium and electrocon-
vulsive therapy. Psychiatric visits were the most frequently used healthcare re-
source, with 8.62 8.25 and 0.96 3.16 (mean SD) programmed and spontaneous
visits per patient-year, respectively. There was a mean of 1.46  5.67 visits to the
psychologist per patient-year. Hospitalization rates since diagnosis and index
event were 0.45 0.83 and 0.34 1.14/patient-year, respectively (time [years] since
diagnosis was 11.13  10.39 overall; BD-I: 11.97  10.46; BD-II: 9.46  9.95). There
were 0.49 4.54, 0.74 4.31 and 0.14 0.68 group therapy, general practitioner and
emergency department visits per patient-year since the index event, respectively.
Overall, there were 85  370 suicide attempts per 1000 patient-year.
CONCLUSIONS: Resource use in this population with BD was considerable, indi-
cating the high burden associated with BD in healthcare systems across different
countries and healthcare settings, representative of everyday clinical practice.
Study funded by AstraZeneca; Clinical Trials Registry: NCT01062607.
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OBJECTIVES: Prescription medications are a cornerstone of mental health treat-
ment. From 1993 to 2003, drug spending was responsible for 46% of the increase in
USmental health expenditures. Psychiatric drugs have also been a driver of spend-
ing on all medications, comprising 26% of Medicaid and 14% of private insurance
drug spending. This study analyzes recent trends in psychiatric prescription drug
spending. Potential drivers were evaluated: generic drug entry; prevalence of uti-
lization; benefit plan design; drug safety concerns; comparative effectiveness re-
search, and new product entry and indications. METHODS: Data were from the
Substance Abuse and Mental Health Services Administration Spending Estimates
and Thomson Reuter’s MarketScan Commercial Database for 1997 through 2008
and from IMS Health. The SAMHSA estimates use similar definitions, data, and
methods as the national health expenditure accounts produced by the CMS and are
based primarily on nationally representative databases. SAMHSA drug spending
was derived from the Medical Expenditure Panel Survey and checked against data
from IMS Health. RESULTS: From 1997 to 2001, national psychiatric medication
spending grew by more than 20% annually. Data from 2001 through 2008 show a
dramatic and steady decline in the spending growth. The average annual growth in
the users per enrollee declined from 7% to 2% from 1997-2001 to 2001-2008. The
average annual increase in costs per day declined from 8% to 2%. Days per user
declined only slightly from 3% to a 2%. A key contributor to the slower price growth
was generic entry, particularly generic antidepressants, encouraged by formulary
design. Generic medications grew from 36% to 70% of all psychiatric prescriptions
from 1997 to 2008. Drug safety concerns also contributed to the spending slow
down. Major comparative effectiveness studies did not have a large impact on
spending growth. CONCLUSIONS: Past high growth in psychiatric drug spending
arising from growth in utilization of branded medications has declined signifi-
cantly, which may have implications for access and new product investment.
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